remdesivir

remdesivir is a broad-spectrum antiviral medication developed by the pharmaceutical company Gilead Sciences. It is a nucleotide analog prodrug that inhibits viral RNA polymerase, and it gained global prominence for its use in treating certain patients with COVID-19. The drug is administered via intravenous infusion and received emergency use authorizations and full approvals from regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency during the COVID-19 pandemic.

Medical uses

The primary medical use is for the treatment of COVID-19 in adults and pediatric patients requiring hospitalization. Regulatory approvals, such as those from the U.S. Food and Drug Administration, are typically based on clinical trials demonstrating reduced time to recovery. It has also been studied and used under protocols for other viral infections, including those caused by the Ebola virus and Marburg virus, following research conducted by institutions like the National Institute of Allergy and Infectious Diseases. Its use is generally recommended within specific windows of symptom onset and is subject to treatment guidelines from organizations such as the World Health Organization and the National Institutes of Health.

Pharmacology

Remdesivir is metabolized intracellularly to its active form, which mimics adenosine triphosphate and acts as an analog of adenosine. The active metabolite, GS-441524 triphosphate, competes with natural substrates for incorporation by the viral RNA-dependent RNA polymerase of viruses like SARS-CoV-2. This incorporation leads to premature termination of viral RNA transcription, effectively halting replication. The drug's pharmacokinetics were characterized in studies supported by Gilead Sciences and academic partners, showing its distribution primarily in plasma with metabolism occurring via hydrolysis.

Adverse effects

Common adverse effects observed in clinical trials include increased levels of liver enzymes such as alanine transaminase and aspartate transaminase, which may indicate potential hepatotoxicity. Other reported effects involve nausea, hypotension, and renal impairment, with some cases documented in reports to the U.S. Food and Drug Administration Adverse Event Reporting System. Infusion-related reactions, including bradycardia and hypersensitivity, have also been noted, necessitating monitoring during administration as per protocols from the Centers for Disease Control and Prevention.

History and society

The development began at Gilead Sciences as part of a program targeting RNA viruses, with early research presented at conferences like the Conference on Retroviruses and Opportunistic Infections. Its profile rose dramatically during the COVID-19 pandemic, following the ACTT-1 trial led by the National Institute of Allergy and Infectious Diseases. Emergency use authorizations were granted by the U.S. Food and Drug Administration in 2020, followed by full approval, while debates over its cost and distribution involved entities like the World Health Organization and governments worldwide. The drug was also a subject of political discussions, including those referenced by the Trump administration.

Research

Ongoing research extends beyond COVID-19, investigating its efficacy against other viruses such as the Nipah virus and Respiratory syncytial virus in studies funded by the National Institutes of Health. Clinical trials, including the SOLIDARITY trial coordinated by the World Health Organization, have evaluated its global impact. Further studies explore combination therapies with agents like baricitinib and its use in pediatric populations, with data published in journals such as The New England Journal of Medicine. Research into novel formulations and broader antiviral applications continues at institutions including the University of North Carolina at Chapel Hill.

Category:Antiviral drugs Category:Gilead Sciences Category:World Health Organization essential medicines